Requip and Quit smoking - a phase IV clinical study of FDA data

Summary:

Quit smoking is reported as a side effect among people who take Requip (ropinirole hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Chantix, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Quit smoking when taking Requip. It is created by eHealthMe based on reports of 21,866 people who have side effects when taking Requip from the FDA, and is updated regularly.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,950 Requip users. Check the latest studies of Requip.

What is Quit smoking?

Quit smoking is found to be associated with 406 drugs and 937 conditions by eHealthMe. Check the latest studies of Quit smoking.

On Jul, 09, 2026

21,866 people reported to have side effects when taking Requip.
Among them, 15 people (0.07%) have Quit smoking.

Among these 15 people:

How long have people been on Requip when they have Quit smoking? *

What is the gender of people who have Quit smoking when taking Requip? *

female: 80 %
male: 20 %

What is the age of people who have Quit smoking when taking Requip? *

What are other drugs people take besides Requip? *

What are other side effects people have besides Quit smoking? *

Weight Increased: 6 people, 40.00%
Hypotension (abnormally low blood pressure): 6 people, 40.00%
Dizziness: 6 people, 40.00%
Weakness: 5 people, 33.33%
Nausea (feeling of having an urge to vomit): 5 people, 33.33%
Drowsiness: 4 people, 26.67%
Weight Loss: 4 people, 26.67%
Back Pain: 4 people, 26.67%
Fatigue (feeling of tiredness): 4 people, 26.67%
Dyspnea (difficult or laboured breathing): 4 people, 26.67%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 13.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 13.33%
Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 6.67%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 6.67%
Insomnia (sleeplessness): 1 person, 6.67%
Infection: 1 person, 6.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 6.67%
High Blood Pressure: 1 person, 6.67%
Heart Rate Irregular: 1 person, 6.67%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Requip and have Quit smoking?

- Check whether Quit smoking is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Requip:

Requip (22,950 reports)

Quit smoking treatments and more:

Quit smoking (89,307 reports)

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Quit smoking:

Quit smoking (406 drugs)

Browse all the conditions that are associated with Quit smoking:

Quit smoking (937 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ropinirole hydrochloride (the active ingredients of Requip) and Requip (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.